Table 1.
Baseline clinical characteristics
| Variables | Values (n = 19) |
|---|---|
| Age, median (Q1, Q3) | 54 (46, 65) |
| Male sex, n (%) | 12 (63.2) |
| Current smoking, n (%) | 0 (0.0) |
| Diabetes, n (%) | 6 (31.6) |
| Hypertension, n (%) | 12 (63.2) |
| Dyslipidaemia, n (%) | 11 (57.9) |
| Renal insufficiency, n (%) | 11 (57.9) |
| Body mass index, kg/m2 | 27.8 ± 4.8 |
| Systolic blood pressure, mmHg | 109 ± 9 |
| Diastolic blood pressure, mmHg | 70 ± 8 |
| Heart rate, bpm | 80 ± 11 |
| Reason for HTX | |
| Ischaemic CMP, n (%) | 3 (15.8) |
| Non-ischaemic CMP, n (%) | 16 (84.2) |
| Years after HTX, median (Q1, Q3) | 2.1 (1.0, 8.0) |
| Donor age, median (Q1, Q3) | 30 (21, 41) |
| Cold ischaemic time, min | 191 ± 34 |
| CMV infection, n (%) | 6 (31.6) |
| LVEF (%) | 65.3 ± 4.5 |
| ISHLT grade | |
| CAV0, n (%) | 7 (36.8) |
| CAV1, n (%) | 10 (52.6) |
| CAV2, n (%) | 1 (5.2) |
| CAV3, n (%) | 1 (5.2) |
| Laboratory data | |
| Total cholesterol (mg/dL) | 200 ± 42 |
| Triglyceride (mg/dL) | 186 ± 106 |
| HDL (mg/dL) | 57 ± 17 |
| LDL (mg/dL) | 107 ± 27 |
| Creatinine (mg/dL) | 1.2 ± 0.3 |
| Fasting blood sugar (mg/dL) | 112.8 ± 61.4 |
| Medication | |
| Aspirin, n (%) | 3 (15.8) |
| Statin, n (%) | 18 (94.7) |
| Steroid, n (%) | 10 (47.4) |
| Azathioprine, n (%) | 3 (15.8) |
| Cyclosporin, n (%) | 3 (15.8) |
| Mycophenolate mofetil, n (%) | 13 (68.4) |
| Sirolimus, n (%) | 13 (68.4) |
| Tacrolimus, n (%) | 3 (15.8) |
BMI, body mass index; CAV, cardiac allograft vasculopathy; CMP, cardiomyopathy; CMV, cytomegalovirus; HDL, high-density lipoprotein; HTX, heart transplantation; ISHLT, International Society for Heart and Lung Transplantation; LDL, low-density lipoprotein.